IMV Inc IMVIF

RE:RE:RE:Our Ovarion Cancer data continues to be better than the rest

[Breakthorough]

We are, if DLBCL data are replicated in Phase 2b, just about one year from accelerated approval in one indication. Which will give time to let ovarian data be mature enough in the meanwhile (the best point in them doesn't seem to be ORR, but duration, and it takes time). Unfortunately, we don't have data abour the Basket Trial ebenthough one can speculate about liver and MSI-H cancers data improving keytruda alone and having a path to market. The real problem seems to be the financing. The ATM is pending over SP.